ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Seattle, WA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Renal Cell Carcinoma
Non-Small-Cell Lung Carcinoma
Triple Negative Breast Cancer
Lung Cancer

Melanoma trials near Seattle, WA, USA:

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Edmonds, Washington, United States and 54 other locations

and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...

Enrolling
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Phase 3

Erasca

Seattle, Washington, United States and 58 other locations

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Bel-sar

Phase 3

Aura Biosciences
Aura Biosciences

Seattle, Washington, United States and 51 other locations

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC...

Active, not recruiting
Melanoma
Drug: nivolumab+rHuPH20
Drug: relatlimab+nivolumab

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Seattle, Washington, United States and 31 other locations

artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma...

Active, not recruiting
Metastatic Uveal Melanoma in the Liver
Biological: Nivolumab
Drug: SD-101

Phase 1

TriSalus Life Sciences

Seattle, Washington, United States and 9 other locations

with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC)....

Active, not recruiting
Melanoma
Non-small Cell Lung Cancer
Biological: LYL845

Phase 1

Lyell Immunopharma

Seattle, Washington, United States and 17 other locations

(IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma...

Enrolling
Advanced Melanoma
Biological: Brenetafusp
Biological: Nivolumab + Relatlimab

Phase 3

Immunocore
Immunocore

Seattle, Washington, United States and 97 other locations

This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to...

Enrolling
Cutaneous Melanoma
Non-small Cell Lung Cancer
Drug: PF-08046049

Phase 1

Seagen, a wholly owned subsidiary of Pfizer

Seattle, Washington, United States and 43 other locations

placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or pl...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Seattle, Washington, United States and 158 other locations

is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better ...

Active, not recruiting
Melanoma
Biological: Pembrolizumab
Biological: V940

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Seattle, Washington, United States and 165 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems